Clinical trials: LAM, open to volunteers
HIV/AIDS
Dolutegravir Plus Lamivudine Simplified Therapy
Dolutegravir (DTG) is one type of integrase inhibitor, lamivudine (3TC) is one type of reverse transcriptase inhibitor, both of which are HIV medicine prevents HIV from self-multiplying, reduces the viral load.
- Trial name
- NCT03884673
- Testing
- DTG+ 3TC
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Guangzhou 8th People's Hospital
Palliative Care
Impact of Medicalized Residential Care (LAM) on the Development of Care Plans for Vulnerable Patients in Palliative Care
The aim of the research is to identify the factors influencing the development of care plans for vulnerable patients admitted to medicalized care facilities (LAM) and in palliative care.
- Trial name
- LAM-SP (NCT07342985)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France